Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This study found that MK-386 selectively suppressed sebum DHT levels in a dose-dependent manner, suggesting potential use for treating acne.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

In this study, researchers found that exosomes derived from Pinctada martensii mucus can effectively inhibit melanin production in melanoma cells and zebrafish without adverse effects, potentially offering a promising therapeutic strategy for treating pigmentary disorders by modulating the NF-κB signaling pathway.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This study by Moussa et al. reported that bicalutamide may help reduce minoxidil-induced hypertrichosis in women with female pattern hair loss.

Minoxidil not effective in preventing chemotherapy-induced hair loss.

This systematic review reports that there is currently no evidence supporting methotrexate for maintaining remission in ulcerative colitis; further large-scale trials are needed to assess its efficacy and safety.

The researchers reported that low-dose methotrexate, in combination with surgical dilatation and local treatments, may improve symptoms in patients with severe stenosing vulvovaginal lichen planus.

This study found that GTx-024 and Danazol had similar effects to dihydrotestosterone on uterine tissue in mice, while GTx-007 showed minimal impact on the parameters tested.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This study reviewed the use of microinfusion of microparticles (MMP®) with methotrexate for treating alopecia frontal fibrosante and found it reduced symptoms associated with the condition and improved specific scalp measurements, showing that the technique is safe and well-tolerated.